INT8075

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.81
First Reported 1986
Last Reported 2011
Negated 0
Speculated 0
Reported most in Abstract
Documents 64
Total Number 65
Disease Relevance 25.41
Pain Relevance 19.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Crh) extracellular region (Crh) response to stress (Crh)
cytoplasm (Crh)
Anatomy Link Frequency
hypothalamus 4
brain 3
spinal cord 3
PVN 2
skin 2
Crh (Mus musculus)
Pain Link Frequency Relevance Heat
Serotonin 50 100.00 Very High Very High Very High
narcan 22 100.00 Very High Very High Very High
Catecholamine 21 100.00 Very High Very High Very High
Enkephalin 4 100.00 Very High Very High Very High
Dynorphin 119 99.98 Very High Very High Very High
Endogenous opioid 7 99.96 Very High Very High Very High
Central nervous system 45 99.92 Very High Very High Very High
Morphine 27 99.90 Very High Very High Very High
Calcitonin gene-related peptide 9 99.90 Very High Very High Very High
GABAergic 32 99.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nociception 24 100.00 Very High Very High Very High
Anxiety Disorder 282 99.92 Very High Very High Very High
Stress 1056 99.82 Very High Very High Very High
Hepatocellular Cancer 26 99.76 Very High Very High Very High
Depression 346 99.36 Very High Very High Very High
Aggression 227 99.00 Very High Very High Very High
Functional Bowel Disorder 2 98.72 Very High Very High Very High
Increased Venous Pressure Under Development 27 98.68 Very High Very High Very High
Abdominal Pain 4 97.76 Very High Very High Very High
Bladder Disease 2 96.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Corticotropin-releasing factor (CRF) has been shown to release endogenous opioid peptides from several rat brain regions.
Localization (release) of CRF in brain associated with endogenous opioid
1) Confidence 0.81 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361439 Disease Relevance 0 Pain Relevance 0.36
Corticotropin-releasing factor (CRF) has been shown to release endogenous opioid peptides from several rat brain regions.
Localization (release) of Corticotropin-releasing factor in brain associated with endogenous opioid
2) Confidence 0.81 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361439 Disease Relevance 0 Pain Relevance 0.36
CRF is produced and released from a variety of cell types, making it difficult to distinguish the specific role of CRF from other neurotransmitters with which it colocalizes.
Localization (released) of CRF associated with neurotransmitter
3) Confidence 0.80 Published 2010 Journal Biol. Psychiatry Section Abstract Doc Link 20303068 Disease Relevance 0.51 Pain Relevance 0.15
Because interleukin-1 has been demonstrated to be a potent releaser of corticotropin-releasing factor (CRF) from the hypothalamus, we were interested to see whether CRF is involved in the antinociception induced by rHu-IL-1 alpha.
Localization (releaser) of corticotropin-releasing factor in hypothalamus associated with antinociception
4) Confidence 0.79 Published 1993 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8365458 Disease Relevance 0 Pain Relevance 0.57
Because interleukin-1 has been demonstrated to be a potent releaser of corticotropin-releasing factor (CRF) from the hypothalamus, we were interested to see whether CRF is involved in the antinociception induced by rHu-IL-1 alpha.
Localization (releaser) of CRF in hypothalamus associated with antinociception
5) Confidence 0.79 Published 1993 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8365458 Disease Relevance 0 Pain Relevance 0.57
Also the dynorphin-releasing effect of CRF was a concentration-related phenomenon, with an estimated EC50 value of 5.3 nM.
Localization (releasing) of CRF associated with dynorphin
6) Confidence 0.75 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361439 Disease Relevance 0 Pain Relevance 0.85
Stimulation by corticotropin-releasing factor of the release of immunoreactive dynorphin A from mouse spinal cords in vitro.
Localization (release) of corticotropin-releasing factor in spinal cords associated with dynorphin
7) Confidence 0.75 Published 1992 Journal Eur. J. Pharmacol. Section Title Doc Link 1361439 Disease Relevance 0 Pain Relevance 0.59
The stimulatory effect of CRF on the release of immunoreactive dynorphin A was abolished by alpha-helical CRF-(9-41), a CRF receptor antagonist, indicating that the dynorphin-releasing effect of CRF was mediated by CRF receptors in the spinal cord.
Localization (releasing) of CRF in spinal cord associated with dynorphin, antagonist and spinal cord
8) Confidence 0.75 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361439 Disease Relevance 0 Pain Relevance 0.85
Since we have demonstrated previously that the actions produced by intrathecally administered CRF in mice involve spinal kappa opioid receptors, experiments were conducted in this study to test the possibility that CRF may release dynorphin A, a putative endogenous kappa opioid agonist, from the mouse spinal cord.
Localization (release) of CRF in spinal cord associated with mu agonist, dynorphin, kappa opioid receptor and spinal cord
9) Confidence 0.75 Published 1992 Journal Eur. J. Pharmacol. Section Abstract Doc Link 1361439 Disease Relevance 0 Pain Relevance 0.48
Corticotropin-releasing factor, given either intracerebroventricularly or intrathecally, caused a dose-dependent inhibition of gastric emptyping and gastrointestinal transit.
Localization (releasing) of Corticotropin-releasing factor
10) Confidence 0.73 Published 1990 Journal Regul. Pept. Section Abstract Doc Link 2343161 Disease Relevance 0 Pain Relevance 0.09
These data suggest that corticotropin-releasing hormone overproduction leads to specific effects in a subset of anxiety paradigms, and that these transgenic mice suffer from a motor deficit in addition to altered anxiety-like behaviour/arousal.
Localization (releasing) of corticotropin-releasing hormone associated with targeted disruption and anxiety disorder
11) Confidence 0.73 Published 2002 Journal Eur. J. Neurosci. Section Abstract Doc Link 12099906 Disease Relevance 0.93 Pain Relevance 0.21
Plasma corticosterone (CORT), adrenocorticotropic hormone (ACTH), and estradiol (E2) levels were determined by RIA, whereas gene expression in brains, lymphoid organs, and skin was measured by quantitative RT-PCR for corticotropin-releasing hormone (Crh), arginine vasopressin (Avp), proopiomelanocortin (Pomc), glucocorticoid receptor (Nr3c1), mineralocorticoid receptor (Nr3c2), corticotropin-releasing hormone receptor types 1 and 2 (Crhr1, Crhr2), interleukin-12 (Il12), tumor necrosis factor-alpha (Tnf alpha), and estrogen receptors type-1 (Esr1) and type-2 (Esr2).
Localization (quantitative) of corticotropin-releasing hormone in skin associated with necrosis and cancer
12) Confidence 0.69 Published 2009 Journal J. Invest. Dermatol. Section Abstract Doc Link 19020552 Disease Relevance 0.88 Pain Relevance 0.09
Plasma corticosterone (CORT), adrenocorticotropic hormone (ACTH), and estradiol (E2) levels were determined by RIA, whereas gene expression in brains, lymphoid organs, and skin was measured by quantitative RT-PCR for corticotropin-releasing hormone (Crh), arginine vasopressin (Avp), proopiomelanocortin (Pomc), glucocorticoid receptor (Nr3c1), mineralocorticoid receptor (Nr3c2), corticotropin-releasing hormone receptor types 1 and 2 (Crhr1, Crhr2), interleukin-12 (Il12), tumor necrosis factor-alpha (Tnf alpha), and estrogen receptors type-1 (Esr1) and type-2 (Esr2).
Localization (quantitative) of Crh in skin associated with necrosis and cancer
13) Confidence 0.69 Published 2009 Journal J. Invest. Dermatol. Section Abstract Doc Link 19020552 Disease Relevance 0.88 Pain Relevance 0.09
TPA, as well as Fsk increases the CRH secretion from hepatoma-derived, homologous NPLC-KC cells (Parkes et al. 1993), or from dissociated hypothalamic primary culture (Wei et al. 2002).
Localization (secretion) of CRH associated with hepatocellular cancer
14) Confidence 0.66 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733102 Disease Relevance 0.10 Pain Relevance 0.19
In further experiments, Schmidt and colleagues showed that in Npy deficient P8 mice deprived for 8hr, the decrease in hypothalamic CRH was attenuated, indicating that the Npy-mediated energy homeostasis pathway is crucial for the stress response in neonatal mice [18].
Localization (decrease) of CRH associated with stress
15) Confidence 0.66 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2827556 Disease Relevance 0.42 Pain Relevance 0.05
Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice.
Localization (releasing) of Corticotropin-releasing factor associated with stress and narcan
16) Confidence 0.65 Published 1986 Journal Regul. Pept. Section Title Doc Link 3492730 Disease Relevance 0.33 Pain Relevance 0.38
In times of stress the hypothalamic-pituitary-adrenal (HPA) axis is activated and releases two neurohormones, corticotropin-releasing hormone (Crh) and arginine vasopressin (Avp), to synergistically stimulate the secretion of adrenocorticotropin hormone (ACTH) from the anterior pituitary, culminating in a rise in circulating glucocorticoids.
Localization (releases) of corticotropin-releasing hormone in anterior pituitary associated with stress
17) Confidence 0.65 Published 2008 Journal Psychoneuroendocrinology Section Abstract Doc Link 18243568 Disease Relevance 0.24 Pain Relevance 0.18
In times of stress the hypothalamic-pituitary-adrenal (HPA) axis is activated and releases two neurohormones, corticotropin-releasing hormone (Crh) and arginine vasopressin (Avp), to synergistically stimulate the secretion of adrenocorticotropin hormone (ACTH) from the anterior pituitary, culminating in a rise in circulating glucocorticoids.
Localization (releases) of Crh in anterior pituitary associated with stress
18) Confidence 0.65 Published 2008 Journal Psychoneuroendocrinology Section Abstract Doc Link 18243568 Disease Relevance 0.24 Pain Relevance 0.19
PURPOSE: Corticotropin-releasing hormone is typically released from the hypothalamus but it has proinflammatory effects outside of the brain, possibly through the activation of mast cells.
Localization (released) of Corticotropin-releasing hormone in brain
19) Confidence 0.64 Published 2006 Journal J. Urol. Section Abstract Doc Link 16890727 Disease Relevance 0.36 Pain Relevance 0.19
The basal secretion of adrenocorticotropin (ACTH) as well as the corticotropin-releasing factor (CRF)-stimulated ACTH released remained unchanged after R(+)- and S(-)-SAL treatment.
Localization (released) of CRF
20) Confidence 0.63 Published 1995 Journal Alcohol Section Abstract Doc Link 8519440 Disease Relevance 0.17 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox